Phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes (MDS).

Trial Profile

Phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes (MDS).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2014

At a glance

  • Drugs Mocetinostat (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 15 May 2014 According to a Mirati Therapeutics media release, initial data are expected by the end of 2014.
    • 07 Apr 2014 New trial record
    • 17 Mar 2014 Mirati Therapeutics conducts a phase II dose confirmation trial of mocetinostat in combination with azacitidine in patients with myelodysplastic syndromes, according to a Mirati Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top